Event-Free Survival
Figure 4 · Panel Event-Free_Survival_According_to_Investigator_Assessment
Panel Event-Free_Survival_According_to_Investigator_Assessment 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han, María Paz Saavedra, Seong Hoon Yoon, Carlos H A Teixeira, Carles Escriu, Alex Martinez-Marti, Collin M Blakely, Yasushi Yatabe, Sanja Dacic, Yuri Rukazenkov, Xiangning Huang, Anupriya Dayal, Jamie E Chaft, NeoADAURA Investigators
J Clin Oncol 43(26) 2875-2887
PURPOSE: Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METHODS: In this randomized, controlled, phase III study, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC were randomly assigned (1:1:1) to receive neoadjuvant osimertinib (80 mg orally once daily for ≥9 weeks) plus platinum-based chemotherapy (once every 3 weeks for three cycles), osimertinib monotherapy (for ≥9 weeks), or placebo plus platinum-based chemotherapy (control), followed by surgical resection. Adjuvant osimertinib was offered to eligible patients after completion of surgery. The primary end point was major pathologic response (MPR) by blinded central pathology review. Event-free survival (EFS) was a secondary end point. RESULTS: Overall, 358 patients were randomly assigned to receive osimertinib plus chemotherapy (121 patients), osimertinib monotherapy (117 patients), or placebo plus chemotherapy (120 patients). Osimertinib plus chemotherapy (MPR rate 26%) and osimertinib monotherapy (25%) demonstrated statistically significant improvement in the MPR rate versus placebo plus chemotherapy (2%), with corresponding odds ratios of 19.82 (95.002% CI, 4.60 to 85.33; P < .0001) and 19.28 (99.9% CI, 1.71 to 217.39; P < .0001), respectively. With 15% data maturity, the EFS rates at 12 months were 93%, 95%, and 83% with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. In the neoadjuvant period, grade ≥3 adverse events of any cause occurred in 36%, 13%, and 33% of patients with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. No new safety concerns were identified. CONCLUSION: Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC.
1 个 Figure · 1 个 KM 面板
Figure 4.. Event-Free Survival, According to Investigator Assessment. The figure shows Kaplan–Meier estimates of EFS among patients in the full analysis set. EFS was measured from the time of randomization. Tick marks indicate censored data, and the vertical lines indicate landmark analyses of EFS at 6- and 12-months following randomization. An event was defined as the first of the following: documented disease progression that precluded surgery or prevented completion of definitive surgery; disease recurrence or a new lesion, local or distant, post-surgery (a new primary malignancy, confirmed by pathology if clinically feasible, was not considered to be an EFS event); for patients who did not undergo surgery for reasons other than disease progression, documented disease progression after the neoadjuvant period; discovery upon attempting surgery that the surgery could not be completed due to disease progression; or death due to any cause. At the interim analysis of EFS, the median duration of follow-up for EFS in all patients was 14.3 (range, < 0.1 to 41.9), 18.3 (range, 2.1 to 41.9), and 14.3 (range, 1.7 to 41.8) months for the osimertinib-plus-chemotherapy, osimertinib-monotherapy, and placebo-plus-chemotherapy groups, respectively; the median duration of follow-up for EFS in censored patients was 15.9 (range, < 0.1 to 41.9), 18.3 (range, 2.2 to 41.9) and 18.8 months (range, 1.7 to 41.8) for each group, respectively. *A 99.8% CI for the HR is presented for the comparison of the osimertinib-plus-chemotherapy versus placebo-plus-chemotherapy; as a statistically significant improvement was not reached for this comparison (a p value < 0.002 was required to declare statistical significance), the treatment difference in EFS between the osimertinib-monotherapy group and the placebo-plus-chemotherapy group was not formally tested. † A 95% CI for the HR is presented for the comparison of osimertinib-monotherapy versus placebo-plus-chemotherapy. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculable; NR, not reached.
Figure 4 · Panel Event-Free_Survival_According_to_Investigator_Assessment
Panel Event-Free_Survival_According_to_Investigator_Assessment 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。